Literature DB >> 7556226

Pharmacodynamic effects of meropenem on gram-negative bacteria.

H Hanberger1, E Svensson, L E Nilsson, M Nilsson.   

Abstract

The in vitro initial killing and post-antibiotic effect (PAE) of meropenem on five gram-negative reference strains were evaluated by bioluminescence assay of bacterial adenosine triphosphate (ATP) and viable count. Morphology studies were performed in parallel. Meropenem showed concentration-dependent long (2-5 h) PAEs on Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia marcescens when assayed by bioluminescence and induced spheroplasts at almost all concentrations. The bioluminescence PAEs reached a maximum response at 4 x MIC. These PAEs of meropenem on Escherichia coli, Klebsiella pneumoniae and Serratia marcescens were longer than corresponding PAEs of imipenem shown in previous studies. The higher affinity of meropenem than imipenem for PBP 3 might explain the longer PAEs obtained with meropenem. However, there was only a very short PAE, no PAE or even a negative PAE when viable count was used as the initial value for the PAE calculation. A strong initial decrease in viability but a less pronounced change in intracellular ATP was registered. Since this initial change in cell numbers is the initial value for the PAE calculation, the length of PAE was highly method dependent. In summary, a strong initial killing and no PAE were shown using viable count as the initial value for the PAE calculation, but a weak initial killing and long PAEs were shown when bioluminescence was used throughout the experiments.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556226     DOI: 10.1007/bf02114893

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  38 in total

1.  The post-antibiotic effect of imipenem and penicillin-binding protein 2.

Authors:  H Erlendsdottir; S Gudmundsson
Journal:  J Antimicrob Chemother       Date:  1992-08       Impact factor: 5.790

2.  Effects of supra- and sub-MIC benzylpenicillin concentrations on group A beta-haemolytic streptococci during the postantibiotic phase in vivo.

Authors:  I Odenholt; S E Holm; O Cars
Journal:  J Antimicrob Chemother       Date:  1990-08       Impact factor: 5.790

3.  Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes.

Authors:  Y Sumita; M Fukasawa; T Okuda
Journal:  J Antibiot (Tokyo)       Date:  1990-03       Impact factor: 2.649

4.  Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.

Authors:  I Odenholt-Tornqvist
Journal:  Scand J Infect Dis Suppl       Date:  1989

5.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

6.  Activity of sub-minimal inhibitory concentrations of aspoxicillin in prolonging the postantibiotic effect against Staphylococcus aureus.

Authors:  T Oshida; T Onta; N Nakanishi; T Matsushita; T Yamaguchi
Journal:  J Antimicrob Chemother       Date:  1990-07       Impact factor: 5.790

7.  Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.

Authors:  M D Kitzis; J F Acar; L Gutmann
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

8.  Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  M V Hayes; D C Orr
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

9.  Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.

Authors:  H Hanberger
Journal:  Scand J Infect Dis Suppl       Date:  1992

Review 10.  The carbapenems: new broad spectrum beta-lactam antibiotics.

Authors:  R C Moellering; G M Eliopoulos; D E Sentochnik
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

View more
  6 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

Review 2.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

4.  Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group.

Authors:  A Nyhlén; B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

Review 5.  Meropenem: an updated review of its use in the management of intra-abdominal infections.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

Review 6.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.